Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 188

1.

Polymeric drug delivery for the treatment of glioblastoma.

Wait SD, Prabhu RS, Burri SH, Atkins TG, Asher AL.

Neuro Oncol. 2015 Mar;17 Suppl 2:ii9-ii23. doi: 10.1093/neuonc/nou360. Review.

2.

First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.

Bock HC, Puchner MJ, Lohmann F, Schütze M, Koll S, Ketter R, Buchalla R, Rainov N, Kantelhardt SR, Rohde V, Giese A.

Neurosurg Rev. 2010 Oct;33(4):441-9. doi: 10.1007/s10143-010-0280-7. Epub 2010 Aug 13.

3.

MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.

Gutenberg A, Bock HC, Brück W, Doerner L, Mehdorn HM, Roggendorf W, Westphal M, Felsberg J, Reifenberger G, Giese A.

Br J Neurosurg. 2013 Dec;27(6):772-8. doi: 10.3109/02688697.2013.791664. Epub 2013 May 11.

PMID:
23662801
5.

Impact of the per-operatory application of GLIADEL wafers (BCNU, carmustine) in combination with temozolomide and radiotherapy in patients with glioblastoma multiforme: efficacy and toxicity.

Miglierini P, Bouchekoua M, Rousseau B, Hieu PD, Malhaire JP, Pradier O.

Clin Neurol Neurosurg. 2012 Nov;114(9):1222-5. doi: 10.1016/j.clineuro.2012.02.056. Epub 2012 Mar 31.

PMID:
22464950
6.

Incorporating BCNU wafers into malignant glioma treatment: European case studies.

Balossier A, Dörner L, Emery E, Heese O, Mehdorn HM, Menei P, Singh J.

Clin Drug Investig. 2010;30(3):195-204. doi: 10.2165/11532900-000000000-00000.

PMID:
20155992
7.

A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients.

Pan E, Mitchell SB, Tsai JS.

J Neurooncol. 2008 Jul;88(3):353-7. doi: 10.1007/s11060-008-9576-7. Epub 2008 Apr 4.

PMID:
18389176
8.

The role of Gliadel wafers in the treatment of newly diagnosed GBM: a meta-analysis.

Xing WK, Shao C, Qi ZY, Yang C, Wang Z.

Drug Des Devel Ther. 2015 Jun 29;9:3341-8. doi: 10.2147/DDDT.S85943. eCollection 2015. Review.

9.

Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management.

Kleinberg LR, Weingart J, Burger P, Carson K, Grossman SA, Li K, Olivi A, Wharam MD, Brem H.

Cancer Invest. 2004;22(1):1-9.

PMID:
15069758
10.

Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results.

Salmaggi A, Milanesi I, Silvani A, Gaviani P, Marchetti M, Fariselli L, Solero CL, Maccagnano C, Casali C, Guzzetti S, Pollo B, Ciusani E, Dimeco F.

J Neurosurg. 2013 Apr;118(4):821-9. doi: 10.3171/2012.12.JNS111893. Epub 2013 Jan 25.

11.

Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.

Affronti ML, Heery CR, Herndon JE 2nd, Rich JN, Reardon DA, Desjardins A, Vredenburgh JJ, Friedman AH, Bigner DD, Friedman HS.

Cancer. 2009 Aug 1;115(15):3501-11. doi: 10.1002/cncr.24398.

12.

Safety and Effectiveness of Bis-Chloroethylnitrosourea Wafer Chemotherapy in Elderly Patients with Recurrent Glioblastoma.

Klein J, Juratli TA, Radev Y, Daubner D, Soucek S, Schackert G, Krex D.

Oncology. 2017;93(1):43-50. doi: 10.1159/000464464. Epub 2017 Apr 11.

PMID:
28395288
13.

The role of interstitial BCNU chemotherapy in the treatment of malignant glioma.

Engelhard HH.

Surg Neurol. 2000 May;53(5):458-64. Review.

PMID:
10874145
14.

Outcome of patients affected by newly diagnosed glioblastoma undergoing surgery assisted by 5-aminolevulinic acid guided resection followed by BCNU wafers implantation: a 3-year follow-up.

Della Puppa A, Lombardi G, Rossetto M, Rustemi O, Berti F, Cecchin D, Gardiman MP, Rolma G, Persano L, Zagonel V, Scienza R.

J Neurooncol. 2017 Jan;131(2):331-340. doi: 10.1007/s11060-016-2301-z. Epub 2016 Oct 18.

PMID:
27757721
15.

Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience.

Akiyama Y, Kimura Y, Enatsu R, Mikami T, Wanibuchi M, Mikuni N.

World Neurosurg. 2018 May;113:e508-e514. doi: 10.1016/j.wneu.2018.02.070. Epub 2018 Feb 21.

PMID:
29476996
16.

Evaluation of post-operative complications associated with repeat resection and BCNU wafer implantation in recurrent glioblastoma.

Samis Zella MA, Wallocha M, Slotty PJ, Isik G, Hänggi D, Schroeteler J, Ewelt C, Steiger HJ, Sabel M.

Acta Neurochir (Wien). 2014 Feb;156(2):313-23. doi: 10.1007/s00701-013-1931-6. Epub 2013 Nov 28.

PMID:
24287680
17.

Carmustine wafer implantation when surgical cavity is communicating with cerebral ventricles: technical considerations on a clinical series.

Della Puppa A, Rossetto M, Ciccarino P, Denaro L, Rotilio A, d'Avella D, Scienza R.

World Neurosurg. 2011 Jul-Aug;76(1-2):156-9; discussion 67-8. doi: 10.1016/j.wneu.2010.10.024.

PMID:
21839967
18.

Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme.

McGirt MJ, Than KD, Weingart JD, Chaichana KL, Attenello FJ, Olivi A, Laterra J, Kleinberg LR, Grossman SA, Brem H, Quiñones-Hinojosa A.

J Neurosurg. 2009 Mar;110(3):583-8. doi: 10.3171/2008.5.17557.

19.

Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies.

Lin SH, Kleinberg LR.

Expert Rev Anticancer Ther. 2008 Mar;8(3):343-59. doi: 10.1586/14737140.8.3.343. Review.

PMID:
18366283
20.

Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis.

Chowdhary SA, Ryken T, Newton HB.

J Neurooncol. 2015 Apr;122(2):367-82. doi: 10.1007/s11060-015-1724-2. Epub 2015 Jan 29.

Supplemental Content

Support Center